Compared with the binding energy of proteins and their respective known ligands, our results were close to or better than the longitudinal positive control, which proved that the top five components in GZD had a stronger effect on its target and might perform a better medicinal effect, such as phaseolinisoflavan acted on MAPK3 and glabrene acted on HRAS; this showed that phaseolinisoflavan and glabrene might be the active ingredients of GZD for treating asthma. The gene discussed is MAPK3; the disease is asthma.